TriSalus Life Sciences Inc
NASDAQ:TLSI
TriSalus Life Sciences Inc
Research & Development
TriSalus Life Sciences Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
T
|
TriSalus Life Sciences Inc
NASDAQ:TLSI
|
Research & Development
-$17.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Flame Acquisition Corp
NYSE:SOC
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Core Scientific Inc
NASDAQ:CORZ
|
Research & Development
-$11.8m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Symbotic Inc
NASDAQ:SYM
|
Research & Development
-$196m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-29%
|
CAGR 10-Years
N/A
|
|
|
Rumble Inc
NASDAQ:RUM
|
Research & Development
-$18.9m
|
CAGR 3-Years
-127%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Cantor Equity Partners Inc
NASDAQ:CEP
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
TriSalus Life Sciences Inc
Glance View
TriSalus Life Sciences Inc is a US-based company operating in industry. The company is headquartered in Westminster, Colorado. The company went IPO on 2020-12-18. TriSalus Life Sciences, Inc. is an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors. The Company’s platform includes devices that utilize a drug delivery technology and a clinical-stage investigational immunotherapy. The Company’s two FDA-cleared devices use its Pressure-Enabled Drug Delivery (PEDD) approach to deliver a range of therapeutics: the TriNav Infusion System for hepatic arterial infusion of liver tumors and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. SD-101, the Company’s investigational immunotherapeutic candidate, is designed to improve patient outcomes by treating the immunosuppressive environment. Patient data generated during Pressure-Enabled Regional Immuno-Oncology (PERIO) clinical trials support the hypothesis that SD-101 delivered through PEDD may has favorable immune effects on the liver and systemically.
See Also
What is TriSalus Life Sciences Inc's Research & Development?
Research & Development
-17.7m
USD
Based on the financial report for Dec 31, 2024, TriSalus Life Sciences Inc's Research & Development amounts to -17.7m USD.
What is TriSalus Life Sciences Inc's Research & Development growth rate?
Research & Development CAGR 1Y
41%
Over the last year, the Research & Development growth was 41%.
